Launch of Aptadir Therapeutics With a Novel Class of RNA Inhibitors [Yahoo! Finance]
Evotec SE (EVO)
NASDAQ:AMEX Investor Relations:
eatonvance.com
Company Research
Source: Yahoo! Finance
Science originates from 3 top international institutions – the Beth Israel Deaconess Medical Center of the Harvard Medical School, the Italian Research National Council (CNR) and the Cancer Science Institute of Singapore First investment for EXTEND technology transfer biotech hub joint venture, comprising CDP Venture Capital SGR, Angelini Ventures and Evotec SE Appointment of Giovanni Amabile as Executive Chairman and acting CEO MILAN, September 24, 2024 BUSINESS WIRE )--Aptadir Therapeutics (Aptadir), a biotech company developing RNA inhibitor-based therapeutics for treating intractable cancers and genetic conditions, announces its launch and the appointment of Giovanni Amabile as Executive Chairman and acting CEO. Aptadir was founded by Dr Annalisa Di Ruscio and Dr Vittorio De Franciscis, both leaders in the field of RNA biology and DNA methylation, alongside Prof. Daniel Tenen, an expert in MDS and leukaemia, and Prof. Marcin Kortylewski, an expert in oligonucleotide immun
Show less
Read more
Impact Snapshot
Event Time:
EVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVO alerts
High impacting Evotec SE news events
Weekly update
A roundup of the hottest topics
EVO
News
- Comment on Media Report [Yahoo! Finance]Yahoo! Finance
- Comment on Media ReportAccesswire
- Evotec SE (NASDAQ: EVO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- Evotec SE (EVOTF) Q3 2024 Earnings Call Highlights: Navigating Market Challenges with Strategic ... [Yahoo! Finance]Yahoo! Finance
- Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions [Yahoo! Finance]Yahoo! Finance